Oncology

Latest News

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

The 2025 Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for enhancing community cancer care.

Community Oncology Reacts to Trump's Drug Pricing Executive Order

By Maggie L. Shaw

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com

5 Things You Should Know About Skin Cancer

By Pearl Steinzor

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com

Patient Navigation Is Nonnegotiable in Cancer Care

By Maggie L. Shaw

May 1st 2025

Liver cancer - Sebastian Kaulitzki - stock.adobe.com.jpg

Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

By AJMC Contributor

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Segment 11 - Why It Is an Exciting Time for Immuno-Oncology

September 30th 2014

Segment 11 - Why It Is an Exciting Time for Immuno-Oncology

The panelists offer their closing remarks regarding immuno-oncology's promises and challenges.

Segment 10 - Paying for Combination Therapies

September 30th 2014

Segment 10 - Paying for Combination Therapies

Michael Kolodziej, MD, considers the benefit of combination therapy vs sequential and whether the increased toxicity of combination therapy is worth it.

Segment 9 - Safety Concerns with Oncolytic Virus Therapies

September 30th 2014

Segment 9 - Safety Concerns with Oncolytic Virus Therapies

Although the oncolytic virus therapy being used in the OPTIM trial has been modified in a way that there should be minimal safety concerns, it should still be handled in a way to limit adverse effects and mutations, according to Kimberly Shafer-Weaver, PhD.

Segment 8 - Overall Survival and Ongoing Combination Clinical Trials

September 30th 2014

Segment 8 - Overall Survival and Ongoing Combination Clinical Trials

While it would be nice to think that one and only one therapy would be effective at combatting cancer, combination therapy is needed, Kimberly Shafer-Weaver, PhD, said.

Segment 7 - Ultimate Measures of Efficiency in Immuno-Oncology

September 30th 2014

Segment 7 - Ultimate Measures of Efficiency in Immuno-Oncology

People are now viewing cancer as a kind of chronic disease that can be held at bay, if it cannot be eliminated entirely, according to Kimberly Shafer-Weaver, PhD.

Segment 6 - Including Patient-Reported Outcomes

September 30th 2014

Segment 6 - Including Patient-Reported Outcomes

Although there are some efforts to marry progression-free survival benefits to clinical benefits defined by the patients, the approach is still in the early stages and needs to be moved forward more quickly, according to Michael Kolodziej, MD.

Segment 5 - Establishing the Value of Immunotherapy in Oncology

September 30th 2014

Segment 5 - Establishing the Value of Immunotherapy in Oncology

Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.

Segment 4 - From Animal Models to Human Bodies

September 30th 2014

Segment 4 - From Animal Models to Human Bodies

Although animal models have shown the anti-CTLA-4 antibodies boost the immune system, the human body is not so simple, Jianda Yuan, MD, PhD, said.

Segment 3 - Pairing Patients with the Right Therapies

September 30th 2014

Segment 3 - Pairing Patients with the Right Therapies

In this clip, Kimberly Shafer-Weaver, PhD, discusses specific biomarkers that could establish utilities for specific patient populations and measuring response to drugs.

Segment 2 - Bringing Latest Innovations to the Public

September 30th 2014

Segment 2 - Bringing Latest Innovations to the Public

Jianda Yuan, MD, PhD, explains the importance of bringing the latest innovations to the public and how more data are showing promising immunologic and clinical responses for different types of cancer.

Segment 1 - Immuno-Oncology Education Outreach Efforts

September 30th 2014

Segment 1 - Immuno-Oncology Education Outreach Efforts

Surabhi Dangi-Garimella, PhD, managing editor of The American Journal of Managed Care's Evidence-Based series led the panel of experts in a discussion on immuno-oncology by first talking about checkpoint inhibitors currently in the market and under development.

September 30th 2014

ESMO 2014: Anamorelin Improves Quality of Life in Lung Cancer Patients

Phase 3 trial data from the ROMANA trials, presented at ESMO found that anamorelin improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia.

September 29th 2014

Xalkori to Treat ROS1-Mutated Lung Cancer Patients?

Xalkori, currently approved for treating NSCLC with ALK rearrangements, reduced the tumor size in nearly 75% of the patients and also extended the remission period.

September 29th 2014

Perjeta Improves Survival in HER2-Positive Breast Cancer Patients

The monoclonal antibody extended survival by nearly 16 months compared to those in the control cohort.

September 29th 2014

ESMO 2014: Nivolumab Promise in Melanoma

Results from the CheckMate-037 trial showed a significant increase in duration of response in patients with advanced melanoma administered nivolumab as second- or third-line therapy

September 26th 2014

Hypercalcaemia as an Early Cancer Biomarker

A study published in the British Journal of Cancer discovered a correlation between hypercalcaemia and the risk of cancer, specifically in males.

September 26th 2014

ESMO Congress: Researchers Identify Barriers to Drug Access

The researchers identified discrepancies across the globe in patient access to life-saving cures for cancer.

September 26th 2014

A New Drug Delivery Vehicle: Anthrax Bacteria

Having delivered antibody mimics to cancer cells in vitro, the research group at MIT that conducted the research is now working on evaluating the technique in tumors grown in mice.

September 25th 2014

Lung Infections May Hamper Efficacy of FDG-PET

A new retrospective study published in JAMA identified that tuberculosis and certain fungal infections in the lungs could hamper the efficient detection of lung cancer by FDG-PET imaging.

September 25th 2014

Treating Late-Stage Lung Cancer Not Cost-Effective: JTO Study

A prospective study published in The Journal of Thoracic Oncology found that the average cost to screen high-risk individuals for developing lung cancer with low-dose computed tomography plus the average cost of curative intent treatment, like surgery, is lower than the average cost to treat advanced stage lung cancer, which quite rarely results in a cure.

September 24th 2014

Proton Radiation-Yea or Nay?

Controversy over the value of proton beam radiation continues to harass clinicians as the therapy emerges to be extremely useful in some, but not all, cancers. Additionally, payers sometimes refuse to cover treatment costs due to lack of evidence of efficacy.

September 24th 2014

NCI's New Approach With The Exceptional Responder Initiative

With the aim of understanding why some patients respond better to a particular drug, NCI has launched the Exceptional Responders Initiative, to generate molecular profiles of tumors that respond well to a particular treatment.

September 24th 2014

PAD2 Overexpression May Promote Skin Cancer

Research published this month in the journal Cancer Research, found that increased expression of the enzyme PAD2 in young mice could lead to skin tumors that could progress to invasive squamous cell carcinoma.

September 23rd 2014

Folowing AACR, ASCO Supports FDA's Guidance for LDTs

The ASCO statement corroborates the need for regulation of laboratory-developed tests, which are increasingly being used to guide personalized treatment in oncology as well as other therapeutic areas.

September 23rd 2014

Should We Pay Doctors Less for Colonoscopy?

Shivan J. Mehta, MD, MBA Scott Manaker, MD, PhD

Due to existing payment structures and practice patterns for colonoscopy, reducing endoscopist reimbursement may diminish access to and quality of colorectal cancer screening.

September 23rd 2014

Updated International Consensus Guidelines for Advanced Breast Cancer Published

The guidelines have been published in 2 journals: Breast and Annals of Oncology.

September 22nd 2014

Amgen's Blinatumomab Get's Breakthrough Status for ALL

The drug is the first in it's class - an antibody designed to engage 2 different targets simultaneously.

September 22nd 2014

New Graphene Biosensor to Detect Cancer Biomarkers

The biosensor, which can detect the oxidative stress marker 8-hydroxydeoxyguanosine, is 5-times more sensitive than the ELISA test that is commonly used to identify biomarkers.

September 19th 2014

Gilead's Zydelig Receives EU Nod for CLL and FL

The approval in CLL is supported primarily by data from a randomized, placebo-controlled phase 3 trial in combination with rituximab in 220 patients with relapsed CLL who were not able to tolerate standard chemotherapy. The approval in FL, is supported by data from a single-arm phase 2 study (Study 101-09) of Zydelig monotherapy in 125 iNHL patients refractory to rituximab and alkylating-agent-containing chemotherapy.

September 19th 2014

Microbubbles: New Carrier for Chemotherapy Delivery

The study, conducted in pancreatic cancer patients in Norway, was presented at the annual meeting of the International Contrast Ultrasound Society in Chicago.

...

150 151 152 153 154 155 156 157 158

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions